Beta-O2 Technologies is a biomedical company developing a proprietary implantable bioreactor, the Air, for the treatment of patients with type 1 diabetes. The Air is a small medical device that is implanted in a minimally invasive procedure. The device, which contains islets of Langerhans, is intended to free patients from insulin injections and continuous monitoring of glucose levels. The device also reduces the risk of hypoglycemic episodes and other complications of the condition. Because the Air device contains living cells, the patient needs to refill the air in the device using a replenishing device, which includes a dedicated injector.